Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Average Rating of “Buy” from Brokerages

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) have received a consensus recommendation of “Buy” from the nine analysts that are currently covering the firm, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $32.50.

Several analysts recently commented on CPRX shares. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 28th. Bank of America reaffirmed a “buy” rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Robert W. Baird boosted their price target on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, March 3rd. Finally, Baird R W raised Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd.

Insider Activity

In other news, insider Gary Ingenito sold 44,904 shares of the company’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total transaction of $991,929.36. Following the transaction, the insider now owns 68,873 shares of the company’s stock, valued at $1,521,404.57. This represents a 39.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Brian Elsbernd sold 62,975 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the transaction, the insider now directly owns 188,564 shares in the company, valued at $4,333,200.72. This trade represents a 25.04 % decrease in their position. The disclosure for this sale can be found here. 11.00% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Large investors have recently made changes to their positions in the company. Steward Partners Investment Advisory LLC bought a new stake in Catalyst Pharmaceuticals in the fourth quarter valued at about $27,000. Park Square Financial Group LLC bought a new stake in Catalyst Pharmaceuticals in the fourth quarter valued at about $29,000. Farther Finance Advisors LLC increased its holdings in Catalyst Pharmaceuticals by 125.1% in the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 1,495 shares during the last quarter. Larson Financial Group LLC increased its holdings in shares of Catalyst Pharmaceuticals by 27,218.2% in the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock worth $60,000 after acquiring an additional 2,994 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB bought a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter worth about $65,000. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Price Performance

Shares of CPRX stock opened at $21.02 on Monday. The stock’s fifty day simple moving average is $22.26 and its 200 day simple moving average is $21.53. The firm has a market cap of $2.55 billion, a price-to-earnings ratio of 17.81, a P/E/G ratio of 3.31 and a beta of 0.84. Catalyst Pharmaceuticals has a one year low of $14.47 and a one year high of $24.64.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.